Clinical trials: Haemostatic
Waldenstrom's Macroglobulinemia
Sildenafil Citrate in Waldenstrom's Macroglobulinemia
The purpose of this study is to determine the effects (good or bad) that sildenafil (Viagra) has on patients with slow growing Waldenstrom's macroglobulinemia (WM).
- Trial name
- NCT00165295
- Testing
- Sildenafil citrate (Viagra)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
The purpose of this study is to evaluate complete response plus (+) very good partial response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination with cyclophosphamide, bortezomib, and…
- Trial name
- NCT02951819
- Testing
- Daratumumab, Cyclophosphamide, Bortezomib
- Where
- 26 sites in United States
- Volunteers
- 101 people
- Sponsor
- Janssen Scientific Affairs, LLC
Peptic Ulcer Bleeding
Study to Evaluate Efficacy and Safety of Wound Dressing Solution Containing EGF in Patients With Peptic Ulcers Bleeding
This is a prospective, single-blinded, randomized study to evaluate the efficacy and safety of CEGP003 in patients with acute peptic ulcers bleeding, compared to endoscopic epinephrine injection therapy.
- Trial name
- CEGP003 (NCT03469167)
- Testing
- CEGP003, Injection Tx
- Volunteers
- 76 people
- Sponsor
- CGBio Inc.
Relapsed/Refractory Multiple Myeloma
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT03309111
- Testing
- ISB 1342
- Where
- 20 sites in United States, France
- Volunteers
- 81 people
- Sponsor
- Ichnos Sciences SA
Multiple Myeloma
Study of FasT CAR-T GC012F Injection NDMM Patients
This is a single-arm, single-center, open-label clinical study to evaluate the safety and efficacy of CAR-T in patients with NDMM.
- Trial name
- NCT05840107
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Changzheng Hospital
Plasma Cell Myeloma
Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma
This trial studies how well strength training works in improving bone health, pain, and quality of life in patients with multiple myeloma.
- Trial name
- NCT03793907
- Testing
- FitBit, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Roswell Park Cancer Institute
Pseudoxanthoma Elasticum
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
This study was designed to evaluate the safety, tolerability, pharmacodynamics (PD) of DS-1211b, and pharmacokinetics (PK) in individuals with Pseudoxanthoma elasticum (PXE).
- Trial name
- NCT05569252
- Testing
- DS-1211b
- Where
- 7 sites in United States, Netherlands
- Volunteers
- 65 people
- Sponsor
- Daiichi Sankyo
COVID-19, Endothelial Dysfunction
The Glycocalyx in COVID-19 Patients. A Pilot Study
The damage of the endothelial glycocalyx is based on microvascular endothelial dysfunction and typical for critical clinical conditions like sepsis, trauma, bleeding, shock, as well as ARDS.
- Conditions
- COVID-19, Endothelial Dysfunction, Coagulation Disorder
- Trial name
- Glycovid-19 (NCT05137249)
- Where
- Austria
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Multiple Myeloma
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone
The purpose of this study was to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with dexamethasone in participants with Relapsed…
- Trial name
- NCT04075721
- Testing
- M3258, M3258 20 mg
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Myeloma Multiple
RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab
Elranatamab is an effective BCMA-targeting bispecific antibody for relapsed/refractory multiple myeloma (RRMM). However, implementation in routine practice remains challenging due to monitoring requirements during step-up dosing…
- Trial name
- RE-RITE (NCT07891871)
- Volunteers
- 400 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Multiple Myeloma, Hodgkin Disease
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy.
- Conditions
- Multiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma
- Trial name
- NCT04459416
- Testing
- Acupuncture, opioid, Assessments
- Where
- 2 sites in United States
- Volunteers
- 299 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed/Refractory Multiple Myeloma
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT04896658
- Testing
- Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Waldenstrom's Macroglobulinemia
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 90% of the patients with Waldenström's macroglobulinemia.
- Trial name
- 8400-401 (NCT02092909)
- Testing
- IMO-8400
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma
The goal of this study is to evaluate the safety of a new type of CAR T-cell, UF-KURE-BCMA, for the treatment of patients with advanced multiple myeloma that has not responded to other therapies.
- Trial name
- NCT07611149
- Testing
- Administration of CAR T-cells at 3 different dose levels
- Volunteers
- 12 people
- Sponsor
- Kure Cells, INC
Multiple Myeloma
Multiple Myeloma Molecular Monitoring Study
The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment.
- Trial name
- M4 (NCT03421132)
- Where
- 9 sites in Canada
- Volunteers
- 96 people
- Sponsor
- Horizon Health Network
Multiple Myeloma, Lymphoma
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous…
- Trial name
- NCT05294055
- Testing
- Etoposide, Cyclophosphamide, Mecapegfilgrastim, day 2
- Where
- 7 sites in China
- Volunteers
- 120 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255684
- Testing
- graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Rochester
Multiple Myeloma
Bortezomib With Melphalan and Prednisone for Multiple Myeloma
The purpose of this study is to assess the efficacy of bortezomib in combination with melphalan and prednisone to achieve complete responses for patients with previously untreated multiple myeloma compared to an historical…
- Trial name
- MVP (NCT00734149)
- Testing
- Bortezomib, Melphalan, Prednisone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Duke University
Gastrointestinal Haemorrhage
Purastat® vs Standard Therapy for Haemostasis During Endoscopic Submucosal Dissection
Endoscopic submucosal dissection (ESD) is an endoscopic resection technique used to treat superficial neoplasia in the gastrointestinal tract.
- Trial name
- NCT02833558
- Testing
- PuraStat®, Electrocautery
- Where
- United Kingdom
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Portsmouth Hospitals NHS Trust
Multiple Myeloma and Plasma Cell Neoplasm
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with relapsed…
- Trial name
- NCT00002907
- Testing
- bryostatin 1
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.